Nothing Special   »   [go: up one dir, main page]

MXPA03001717A - Method for treatment of migraine. - Google Patents

Method for treatment of migraine.

Info

Publication number
MXPA03001717A
MXPA03001717A MXPA03001717A MXPA03001717A MXPA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A
Authority
MX
Mexico
Prior art keywords
migraine
treatment
Prior art date
Application number
MXPA03001717A
Other languages
Spanish (es)
Inventor
Hartmut Porst
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of MXPA03001717A publication Critical patent/MXPA03001717A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA03001717A 2000-08-30 2001-08-27 Method for treatment of migraine. MXPA03001717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22908300P 2000-08-30 2000-08-30
PCT/US2001/026740 WO2002019213A2 (en) 2000-08-30 2001-08-27 Method for treatment of migraine using pde5 inhibitors

Publications (1)

Publication Number Publication Date
MXPA03001717A true MXPA03001717A (en) 2003-09-22

Family

ID=22859786

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001717A MXPA03001717A (en) 2000-08-30 2001-08-27 Method for treatment of migraine.

Country Status (8)

Country Link
EP (1) EP1313478A2 (en)
JP (1) JP2004507514A (en)
CN (1) CN1471397A (en)
AU (1) AU2001286832A1 (en)
BR (1) BR0113644A (en)
CA (1) CA2419623A1 (en)
MX (1) MXPA03001717A (en)
WO (1) WO2002019213A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
PL2425820T3 (en) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20080260643A1 (en) 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
WO2009134336A1 (en) 2008-04-28 2009-11-05 Zogenix, Inc. Novel formulations for treatment of migraine
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
JP2015506359A (en) 2012-01-04 2015-03-02 ウェルズリー ファーマスーティカルズ、エルエルシー Delayed release formulations for reducing urination frequency and methods of use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
CN107661326A (en) * 2012-07-27 2018-02-06 韦尔斯利医药有限公司 Pharmaceutical preparations for enuresis and methods of use thereof
WO2014100351A2 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
JP2017114764A (en) * 2014-04-25 2017-06-29 武田薬品工業株式会社 Migraine therapeutic agent
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof

Also Published As

Publication number Publication date
BR0113644A (en) 2003-07-29
CA2419623A1 (en) 2002-03-07
EP1313478A2 (en) 2003-05-28
WO2002019213A2 (en) 2002-03-07
JP2004507514A (en) 2004-03-11
CN1471397A (en) 2004-01-28
AU2001286832A1 (en) 2002-03-13
WO2002019213A3 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
GB0014969D0 (en) Novel method of treatment
MXPA03001717A (en) Method for treatment of migraine.
EP1414464A4 (en) Method for treating glaucoma v
ZA200108446B (en) Novel method of treatment.
ZA200300418B (en) Method of treating cardiovascular disease.
GB0129976D0 (en) Treatment method
EP1465968A4 (en) Methods for treating deodorizer distillate
HK1064261A1 (en) Method for the treatment of tobacco.
EP1581234A4 (en) Methods for treating migraine
AU2001286983A1 (en) Method of treatment
ZA200108494B (en) Method of treating cartilage damage.
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
AP2004003070A0 (en) The method of treating cancer.
EP1389105A4 (en) Method of treatment
GB0120147D0 (en) Treatment method
MXPA03003347A (en) Method of purifying plavastatin.
MXPA03004017A (en) Method for the treatment of inflammation.
GB0112216D0 (en) Method of treatment
GB0008921D0 (en) Method of treatment
GB0026838D0 (en) Treatment method
ZA200101058B (en) Process for the treatment of gases.
GB0118892D0 (en) Method of treatment
HUP0105152A3 (en) Method for treatment of headache
ZA200007396B (en) Method of treatment.
AU2002212876A1 (en) Method for integrated water treatment